| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_78b200401214cf90536d4ac7fcb6ff04 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-407
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-052
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-007
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0073 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-14 |
| filingDate |
2019-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d5d5bdae7e50495abb7d4769e1038e3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d499a7906505096a3a1fc181a18dfd9e |
| publicationDate |
2021-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3793545-A1 |
| titleOfInvention |
Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form beta inhibitors |
| abstract |
Pharmaceutical compositions and methods are described which rely upon glycogen synthase kinase 3 (form β; GSK 3 β) inhibitors, most preferably 9-ING-41, to inhibit fibrotic pulmonary remodeling in vivo including proliferation and differentiation of myofibroblasts to fibrotic fibroblasts in several mouse models. Therapeutic targeting of GSK-3β with the clinically useful specific inhibitor, 9-ING-41, mitigates fibrotic pulmonary remodeling in vivo and provides a mode of therapy of human IPF by specific GSK-3β inhibition with 9-ING-41. |
| priorityDate |
2018-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |